Baines, A. C. & Brodsky, R. A. Complementopathies. Blood Rev. 31, 213-223 (2017).
Bao, L., Cunningham, P. N. & Quigg, R. J. Complement in lupus nephritis: new perspectives. Kidney Dis. (Basel) 1, 91-99 (2015).
Banda, N. K. et al. Targeted inhibition of the complement alternative pathway with complement receptor 2 and factor H attenuates collagen antibody-induced arthritis in mice. J. Immunol. 183, 5928-5937 (2009).
Banda, N. K. et al. Alternative complement pathway activation is essential for inflammation and joint destruction in the passive transfer model of collagen-induced arthritis. J. Immunol. 177, 1904-1912 (2006).
Banda, N. K., Takahashi, K., Wood, A. K., Holers, V. M. & Arend, W. P. Pathogenic complement activation in collagen antibody-induced arthritis in mice requires amplification by the alternative pathway. J. Immunol. 179, 4101-4109 (2007).
Banda, N. K. et al. Role of C3a receptors, C5a receptors, and complement protein C6 deficiency in collagen antibody-induced arthritis in mice. J. Immunol. 188, 1469-1478 (2012).
Banda, N. K. et al. Essential role for the lectin pathway in collagen antibody-induced arthritis revealed through use of adenovirus programming complement inhibitor MAp44 expression. J. Immunol. 193, 2455-2468 (2014).
Bekker, P. et al. Characterization of pharmacologic and pharmacokinetic properties of CCX168, a potent and selective orally administered complement 5a receptor inhibitor, based on preclinical evaluation and randomized phase 1 clinical study. PLoS ONE 11, e0164646 (2016).
Beurskens, F. J., van Schaarenburg, R. A. & Trouw, L. A. C1q, antibodies and anti C1q autoantibodies. Mol. Immunol. 68, 6-13 (2015).
Blom, A. M., Osterborg, A., Mollnes, T. E. & Okroj, M. Antibodies reactive to cleaved sites in complement proteins enable highly specific measurement of soluble markers of complement activation. Mol. Immunol. 66, 164-170 (2015).
Blom, A. M., Nandakumar, K. S. & Holmdahl, R. C4b binding protein (C4BP) inhibits development of experimental arthritis in mice. Ann. Rheum. Dis. 68, 136-142 (2009).
Bloom, A. C. et al. Deletion of the membrane complement inhibitor CD59a drives age and gender-dependent alterations to bone phenotype in mice. Bone 84, 253-261 (2016).
Bradley, K. et al. Synthesis of classical pathway complement components by chondrocytes. Immunology 88, 648-656 (1996).
Brodeur, J. P., Ruddy, S., Schwartz, L. B. & Moxley, G. Synovial fluid levels of complement SC5b 9 and fragment Bb are elevated in patients with rheumatoid arthritis. Arthritis Rheum. 34, 1531-1537 (1991).
Camous, L. et al. Complement alternative pathway acts as a positive feedback amplification of neutrophil activation. Blood 117, 1340-1349 (2011).
Chen, M., Jayne, D. R. W. & Zhao, M. H. Complement in ANCA-associated vasculitis: mechanisms and implications for management. Nat. Rev. Nephrol. 13, 359-367 (2017).
Chen, M., Kallenberg, C. G. & Zhao, M. H. ANCA-negative pauci-immune crescentic glomerulonephritis. Nat. Rev. Nephrol. 5, 313-318 (2009).
Chimenti, M. S., Ballanti, E., Triggianese, P. & Perricone, R. Vasculitides and the complement system: a comprehensive review. Clin. Rev. Allergy Immunol. 49, 333-346 (2015).
Cicardi, M. & Johnston, D. T. Hereditary and acquired complement component 1 esterase inhibitor deficiency: a review for the hematologist. Acta Haematol. 127, 208-220 (2012).
Cornec, D., Cornec Le Gall, E., Fervenza, F. C. & Specks, U. ANCA-associated vasculitis - clinical utility of using ANCA specificity to classify patients. Nat. Rev. Rheumatol. 12, 570-579 (2016).
Corvetta, A. et al. Terminal complement complex in synovial tissue from patients affected by rheumatoid arthritis, osteoarthritis and acute joint trauma. Clin. Exp. Rheumatol. 10, 433-438 (1992).
Crow, M. K. & Kirou, K. A. Interferon-alpha in systemic lupus erythematosus. Curr. Opin. Rheumatol. 16, 541-547 (2004).
Degn, S. E., Hansen, A. G., Steffensen, R., Jacobsen, C., Jensenius, J. C., Thiel, S. MAp44, a human protein associated with pattern recognition molecules of the complement system and regulating the lectin pathway of complement activation. J Immunol. 1950, (183):7371-7378 (2009).
Dragon-Durey, M. A., Blanc, C., Marinozzi, M. C., van Schaarenburg, R. A. & Trouw, L. A. Autoantibodies against complement components and functional consequences. Mol. Immunol. 56, 213-221 (2013).
Durigutto, P. et al. Prevention of arthritis by locally synthesized recombinant antibody neutralizing complement component C5. PLoS ONE 8, e58696 (2013).
Falk, R. J., Terrell, R. S., Charles, L. A. & Jennette, J. C. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc. Natl Acad. Sci. USA 87, 4115-4119 (1990).
Ferreira, V., Valck, C., Sánchez, G., Gingras, A., Tzima, S., Molina, M. C., et al. The classical activation pathway of the human complement system is specifically inhibited by calreticulin from Trypanosoma cruzi. J Immunol. 1950 (172), 3042-3050 (2004).
Gaboriaud, C., Gupta, R. K., Martin, L., Lacroix, M., Serre, L., Teillet, F., et al. The serine protease domain of MASP-3: enzymatic properties and crystal structure in complex with ecotin. PLoS One 8, e67962 (2013).
Galanakis, D. K., & Ghebrehiwet, B. A unique property of a plasma proteoglycan, the C1q inhibitor. An anticoagulant state resulting from its binding to fibrinogen. J Clin Invest. 93, 303-310 (1994).
Ghebrehiwet, B & Galanakis, D. K. C1q inhibitor (chondroitin-4-sulfate proteoglycan): structure and function. Behring Inst Mitt. 93, 214-223 (1993).
Grumach, A. S. & Kirschfink, M. Are complement deficiencies really rare? Overview on prevalence, clinical importance and modern diagnostic approach. Mol. Immunol. 61, 110-117 (2014).
Gomes, R. C. et al. Features of 847 childhood-onset systemic lupus erythematosus patients in three age groups at diagnosis: a Brazilian multicenter study. Arthritis Care Res. (Hoboken) 68, 1736-1741 (2016).
Gou, S. J., Yuan, J., Chen, M., Yu, F. & Zhao, M. H. Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Kidney Int. 83, 129-137 (2013).
Happonen, K. E. et al. Regulation of complement by cartilage oligomeric matrix protein allows for a novel molecular diagnostic principle in rheumatoid arthritis. Arthritis Rheum. 62, 3574-3583 (2010).
Hill, A., DeZern, A. E., Kinoshita, T. & Brodsky, R. A. Paroxysmal nocturnal haemoglobinuria. Nat. Rev. Dis. Primers 3, 17028 (2017).
Hillmen, P. et al. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. Am. J. Hematol. 85, 553-559 (2010).
Hillmen, P. et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 355, 1233-1243 (2006).
Hirt-Minkowski, P. et al. A trial of complement inhibition in a patient with cryoglobulin-induced glomerulonephritis. Case. Rep. Nephrol. Urol. 2, 38-45 (2012).
Hogasen, K. et al. Terminal complement pathway activation and low lysis inhibitors in rheumatoid arthritis synovial fluid. J. Rheumatol. 22, 24-28 (1995).
Holers, V. M. Targeting mechanisms at sites of complement activation for imaging and therapy. Immunobiology 221, 726-732 (2016).
Jachiet, M. et al. The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: data from a French nationwide study of fifty-seven patients. Arthritis Rheumatol. 67, 527-534 (2015).
Jennette, J. C. et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 65, 1-11 (2013).
Ji, H. et al. Arthritis critically dependent on innate immune system players. Immunity 16, 157-168 (2002).
Jiang, H. X., Siegel, J. N. & Gewurz, H. Binding and complement activation by C-reactive protein via the collagen-like region of C1q and inhibition of these reactions by monoclonal antibodies to C-reactive protein and C1q. J. Immunol. 146, 2324-2330 (1991).
Jose, P. J., Moss, I. K., Maini, R. N. & Williams, T. J. Measurement of the chemotactic complement fragment C5a in rheumatoid synovial fluids by radioimmunoassay: role of C5a in the acute inflammatory phase. Ann. Rheum. Dis. 49, 747-752 (1990).
Kaplan, R. A. et al. Metabolism of C4 and factor B in rheumatoid arthritis. Relation to rheumatoid factor. Arthritis Rheum. 23, 911-920 (1980).
Katschke, K. J. Jr et al. A novel inhibitor of the alternative pathway of complement reverses inflammation and bone destruction in experimental arthritis. J. Exp. Med. 204, 1319-1325 (2007).
Kemp, P. A. et al. Immunohistochemical determination of complement activation in joint tissues of patients with rheumatoid arthritis and osteoarthritis using neoantigen-specific monoclonal antibodies. J. Clin. Lab. Immunol. 37, 147-162 (1992).
Kotimaa, J. et al. Sex matters: systemic complement activity of female C57BL/6J and BALB/cJ mice is limited by serum terminal pathway components. Mol. Immunol. 76, 13-21 (2016).
Leffler, J. et al. Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease. J. Immunol. 188, 3522-3531 (2012).
Leffler, J., Bengtsson, A. A. & Blom, A. M. The complement system in systemic lupus erythematosus: an update. Ann. Rheum. Dis. 73, 1601-1606 (2014).
Legendre, C. M. et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N. Engl. J. Med. 368, 2169-2181 (2013).
Lepus, C. M. et al. Brief report: carboxypeptidase B serves as a protective mediator in osteoarthritis. Arthritis Rheumatol. 66, 101-106 (2014).
Lintner, K. E. et al. Early components of the complement classical activation pathway in human systemic autoimmune diseases. Front. Immunol. 7, 36 (2016).
Liszewski, M. K., Farries, T. C., Lublin, D. M., Rooney, I. A., Atkinson, J. P. Control of the complement system. Adv Immunol. 61, 201-283 (1996).
Lood, C. et al. C1q inhibits immune complex-induced interferon-alpha production in plasmacytoid dendritic cells: a novel link between C1q deficiency and systemic lupus erythematosus pathogenesis. Arthritis Rheum. 60, 3081-3090 (2009).
Macedo, A. C. & Isaac, L. Systemic lupus erythematosus and deficiencies of early components of the complement classical pathway. Front. Immunol. 7, 55 (2016).
Macor, P. et al. Treatment of experimental arthritis by targeting synovial endothelium with a neutralizing recombinant antibody to C5. Arthritis Rheum. 64, 2559-2567 (2012).
Mahler, M., van Schaarenburg, R. A. & Trouw, L. A. Anti C1q autoantibodies, novel tests, and clinical consequences. Front. Immunol. 4, 117 (2013).
Manderson, A. P., Botto, M. & Walport, M. J. The role of complement in the development of systemic lupus erythematosus. Annu. Rev. Immunol. 22, 431-456 (2004).
Martin, M. & Blom, A. M. Complement in removal of the dead - balancing inflammation. Immunol. Rev. 274, 218-232 (2016).
McInnes, I. B. & Schett, G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet 389, 2328-2337 (2017).
Mehta, G., Scheinman, R. I., Holers, V. M. & Banda, N. K. A new approach for the treatment of arthritis in mice with a novel conjugate of an anti- C5aR1 antibody and C5 siRNA. J. Immunol. 194, 5446-5454 (2015).
Melin Furst, C. et al. The C type lectin of the aggrecan G3 domain activates complement. PLoS ONE 8, e61407 (2013).
Melin Furst, C. et al. Quantitative mass spectrometry to study inflammatory cartilage degradation and resulting interactions with the complement system. J. Immunol. 197, 3415-3424 (2016).
Merle, N. S., Church, S. E.,
Fremeaux-Bacchi, V., Roumenina, L. T. Complement System Part I - Molecular Mechanisms of Activation and Regulation. Front Immunol. 2 (6), 262 (2015).
Morgan, B. P., Boyd, C. & Bubeck, D. Molecular cell biology of complement membrane attack. Semin. Cell Dev. Biol. http://dx.doi.org/10.1016/j. semcdb.2017.06.009 (2017).
Morgan, B. P., Daniels, R. H. & Williams, B. D. Measurement of terminal complement complexes in rheumatoid arthritis. Clin. Exp. Immunol. 73, 473-478 (1988).
Morgan, B. P. & Harris, C. L. Complement, a target for therapy in inflammatory and degenerative diseases. Nat. Rev. Drug Discov. 14, 857-877 (2015).
Moxley, G. & Ruddy, S. Elevated C3 anaphylatoxin levels in synovial fluids from patients with rheumatoid arthritis. Arthritis Rheum. 28, 1089-1095 (1985).
Nauta, A. J. et al. Direct binding of C1q to apoptotic cells and cell blebs induces complement activation. Eur. J. Immunol. 32, 1726-1736 (2002).
Nester, C. M. et al. Atypical aHUS: state of the art. Mol. Immunol. 67, 31-42 (2015).
Nilsson, B. & Ekdahl, K. N. Complement diagnostics: concepts, indications, and practical guidelines. Clin. Dev. Immunol. 2012, 962702 (2012).
Okroj, M., Heinegard, D., Holmdahl, R. & Blom, A. M. Rheumatoid arthritis and the complement system. Ann. Med. 39, 517-530 (2007).
Paréj, K., Dobó, J., Závodszky, P., Gál, P. The control of the complement lectin pathway activation revisited: both C1-inhibitor and antithrombin are likely physiological inhibitors, while α2-macroglobulin is not. Mol Immunol. 54, 415-422 (2013).
Presanis, J. S., Hajela, K., Ambrus, G., Gál, P., Sim, R. B. Differential substrate and inhibitor profiles for human MASP-1 and MASP-2. Mol Immunol. 40, 921-929 (2004).
Prohaszka, Z., Nilsson, B., Frazer-Abel, A. & Kirschfink, M. Complement analysis 2016: clinical indications, laboratory diagnostics and quality control. Immunobiology 221, 1247-1258 (2016).
Ram, S., Lewis, L. A. & Rice, P. A. Infections of people with complement deficiencies and patients who have undergone splenectomy. Clin. Microbiol. Rev. 23, 740-780 (2010).
Ricklin, D., Reis, E. S. & Lambris, J. D. Complement in disease: a defence system turning offensive. Nat. Rev. Nephrol. 12, 383-401 (2016).
Ritter, S. Y. et al. Proteomic analysis of synovial fluid from the osteoarthritic knee: comparison with transcriptome analyses of joint tissues. Arthritis Rheum. 65, 981-992 (2013).
Roumenina, L. T., Radanova, M., Atanasov, B. P., Popov, K. T., Kaveri, S. V., LacroixDesmazes, S., et al. Heme interacts with c1q and inhibits the classical complement pathway. J Biol Chem. 286, 16459-16469 (2011).
Schreiber, A. et al. C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J. Am. Soc. Nephrol. 20, 289-298 (2009).
Seelen, M. A. et al. Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. J. Immunol. Methods 296, 187-198 (2005).
Sekine, H. et al. Complement component C3 is not required for full expression of immune complex glomerulonephritis in MRL/lpr mice. J. Immunol. 166, 6444-6451 (2001).
Sethi, S. et al. Complement activation in pauci-immune necrotizing and crescentic glomerulonephritis: results of a proteomic analysis. Nephrol. Dial. Transplant. 32, i139-i145 (2017).
Sjoberg, A. P. et al. Short leucine-rich glycoproteins of the extracellular matrix display diverse patterns of complement interaction and activation. Mol. Immunol. 46, 830-839 (2009).
Sjoberg, A., Onnerfjord, P., Morgelin, M., Heinegard, D. & Blom, A. M. The extracellular matrix and inflammation: fibromodulin activates the classical pathway of complement by directly binding C1q. J. Biol. Chem. 280, 32301-32308 (2005).
Son, M., Santiago-Schwarz, F., Al Abed, Y. & Diamond, B. C1q limits dendritic cell differentiation and activation by engaging LAIR 1. Proc. Natl Acad. Sci. USA 109, E3160-E3167 (2012).
Strait, R. T. et al. IgG1 protects against renal disease in a mouse model of cryoglobulinaemia. Nature 517, 501-504 (2015).
Struglics, A. et al. The complement system is activated in synovial fluid from subjects with knee injury and from patients with osteoarthritis. Arthritis Res. Ther. 18, 223 (2016).
Sturfelt, G. & Truedsson, L. Complement in the immunopathogenesis of rheumatic disease. Nat. Rev. Rheumatol. 8, 458-468 (2012).
Swaak, A. J. et al. An analysis of the levels of complement components in the synovial fluid in rheumatic diseases. Clin. Rheumatol. 6, 350-357 (1987).
Taylor, P. R. et al. A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. J. Exp. Med. 192, 359-366 (2000).
Trendelenburg, M. et al. The role of complement in cryoglobulin-induced immune complex glomerulonephritis. J. Immunol. 175, 6909-6914 (2005).
Trendelenburg, M., Marfurt, J., Gerber, I., Tyndall, A. & Schifferli, J. A. Lack of occurrence of severe lupus nephritis among anti C1q autoantibody-negative patients. Arthritis Rheum. 42, 187-188 (1999).
Trouw, L. A. et al. Anti C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q containing immune complexes. J. Clin. Invest. 114, 679-688 (2004).
Trouw, L. A., Blom, A. M. & Gasque, P. Role of complement and complement regulators in the removal of apoptotic cells. Mol. Immunol. 45, 1199-1207 (2008).
Trouw, L. A., Rispens, T. & Toes, R. E. Beyond citrullination: other post-translational protein modifications in rheumatoid arthritis. Nat. Rev. Rheumatol. 13, 331-339 (2017).
Van Schravendijk, M. R. & Dwek, R. A. Interaction of C1q with DNA. Mol. Immunol. 19, 1179-1187 (1982).
Walport, M. J., Davies, K. A., Morley, B. J. & Botto, M. Complement deficiency and autoimmunity. Ann. NY Acad. Sci. 815, 267-281 (1997).
Wang, Q. et al. Identification of a central role for complement in osteoarthritis. Nat. Med. 17, 1674-1679 (2011).
Wang, Y., Rollins, S. A., Madri, J. A. & Matis, L. A. Anti C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc. Natl Acad. Sci. USA 92, 8955-8959 (1995).
Wang, H., Wang, C., Zhao, M. H. & Chen, M. Neutrophil extracellular traps can activate alternative complement pathways. Clin. Exp. Immunol. 181, 518-527 (2015).
Wisnieski, J. J. & Jones, S. M. IgG autoantibody to the collagen-like region of Clq in hypocomplementemic urticarial vasculitis syndrome, systemic lupus erythematosus, and 6 other musculoskeletal or rheumatic diseases. J. Rheumatol. 19, 884-888 (1992).
Xiao, H., Schreiber, A., Heeringa, P., Falk, R. J. & Jennette, J. C. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am. J. Pathol. 170, 52-64 (2007).
Xing, G. Q. et al. Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauci-immune vasculitis. J. Clin. Immunol. 29, 282-291 (2009).
Yadav, S., Gupta, S., Selvaraj, C., Doharey, P. K., Verma, A., Singh, S. K., et al. In silico and in vitro studies on the protein-protein interactions between Brugia malayi immunomodulatory protein calreticulin and human C1q. PLoS One 9:e106413 (2014).
Yuan, J. et al. C5a and its receptors in human anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Arthritis Res. Ther. 14, R140 (2012).
